Aptose Biosciences (APTO) is Likely to Outperform on Increased Luxeptinib Activity - H.C. Wainwright
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $9.00 price target on Aptose Biosciences (NASDAQ: APTO) on the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
